dallas glp-1 lawsuit Effects of Weight Loss Medications Explained Wegovy® Lawsuit | July 2026

Weight-loss medications have a role in obesity and chronic disease, but without stronger safeguards we risk harming users and driving up long-term health system costs

SGLT2 inhibitors also appear to reduce risk of HF hospitalization and progression of kidney disease in patients with established ASCVD, multiple risk factors for ASCVD, or DKD

Institute of Medicine (U.S.) Committee to Study Priorities for Vaccine Development

Toma Pfeffer, CEO of Bayer UK and Ireland, zeroed in on the structural problem: Most healthcare systems were structurally incentivized to look no further than the next 12 months. His call for collaboration on reimbursement models reflects Bayers bet that the winners in cell and gene therapy will be those with the patience and capital to design trials that anticipate health technology assessment endpoints from the start

Echeverri emphasizes that the goal isnt just weight loss

Mansur RB, Ahmed J, Cha DS, Woldeyohannes HO, Subramaniapillai M, Lovshin J, et al